TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer

Cancer Research

Volumn 71, Issue 5, 2011, Pages 1607-1614

  Salaun, Bruno ^a   Zitvogel, Laurence ^b,c,d   Asselin Paturel, Carine ^e   Morel, Yannis ^e   Chemin, Karine ^e   Dubois, Clarisse ^e   Massacrier, Catherine ^e   Conforti, Rosa ^b,c   Chenard, Marie Pierre ^f   Sabourin, Jean Christophe ^g   Goubar, Aicha ^b   Lebecque, Serge ^h   Pierres, Michel ⁱ   Rimoldi, Donata ^a   Romero, Pedro ^a   Andre, Fabrice ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c INSERM   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e INNATE PHARMA   (France)

^f HÔPITAL DE HAUTEPIERRE   (France)

^g ROUEN UNIVERSITY HOSPITAL   (France)

^h CENTRE LÉON BÉRARD   (France)

ⁱ CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DOUBLE STRANDED RNA; MONOCLONAL ANTIBODY; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 3 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RELAPSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SPLEEN CELL; TISSUE MICROARRAY; TUMOR CELL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RNA, DOUBLE-STRANDED; TOLL-LIKE RECEPTOR 3; TUMOR MARKERS, BIOLOGICAL;

EID: 79952212690     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3490     Document Type: Article

References (32)

1. Tan AR, Swain SM. Ongoing adjuvant trials with trastuzumab in breast cancer. Semin Oncol 2003;30:54-64. (Pubitemid 37433397)
2. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001;413:732-8. (Pubitemid 33009951)
3. Muzio M, Bosisio D, Polentarutti N, D'amico G, Stoppacciaro A, Mancinelli R, et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 2000;164:5998-6004. (Pubitemid 30389848)
4. Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, Chignard M, et al. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem 2005;280:5571-80. (Pubitemid 40280035)
5. Li K, Chen Z, Kato N, Gale M Jr., Lemon SM. Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. J Biol Chem 2005;280:16739-47. Epub 2005 Feb 28. (Pubitemid 41389131)
6. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006;176:4894-901.
7. Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P. Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res 2007;13:4565-74.
8. Conforti R, Ma Y, Morel Y, Paturel C, Terme M, Viaud S, et al. Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res 2010;70:490-500.
9. Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE, Eguchi J, et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med 2007;5:10.
10. Jeung HC, Moon YW, Rha SY, Yoo NC, Roh JK, Noh SH, et al. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Ann Oncol 2008;19:520-6. (Pubitemid 351325674)
11. Kemeny N, Yagoda A, Wang Y, Field K, Wrobleski H, Whitmore W. Randomized trial of standard therapy with or without poly I:C in patients with superficial bladder cancer. Cancer 1981;48:2154-7. (Pubitemid 12231583)
12. Lacour J, Lacour F, Spira A, Michelson M, Petit JY, Delage G, et al. Adjuvant treatment with polyadenylic-polyuridylic acid (Polya.Polyu) in operable breast cancer. Lancet 1980;2:161-4. (Pubitemid 10084713)
13. Lacour J, Laplanche A, Malafosse M, Gallot D, Julien M, Rotman N, et al. Polyadenylic-polyuridylic acid as an adjuvant in resectable colorectal carcinoma: a 6 1/2 year follow-up analysis of a multicentric double blind randomized trial. Eur J Surg Oncol 1992;18:599-604.
14. Laplanche A, Alzieu L, Delozier T, Berlie J, Veyret C, Fargeot P, et al. Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: a 14 year follow-up analysis of a randomized trial of the Federation Nationale des Centres de Lutte contre le Cancer (FNCLCC). Breast Cancer Res Treat 2000;64:189-91. (Pubitemid 32010336)
15. Pawlicki M, Jonca M, Krzemieniecki K, Zuchowska-Vogelgesang B. [Results of adjuvant therapy with the preparation Poly-a Poly-u in patients with malignant melanoma during a 10-year observation]. Wiad Lek 1993;46:912-4.
16. Lacour J, Laplanche A, Delozier T, Berlie J, Mourali N, Julien JP, et al. Polyadenylic-polyuridylic acid plus locoregional and pelvic radiotherapy versus chemotherapy with CMF as adjuvants in operable breast cancer. A 6 1/2 year follow-up analysis of a randomized trial of the French Federation of Cancer Centers (F.F.C.C.). Breast Cancer Res Treat 1991;19:15-21.
17. Colucci F, Soudais C, Rosmaraki E, Vanes L, Tybulewicz VL, Di Santo JP. Dissecting NK cell development using a novel alymphoid mouse model: investigating the role of the c-abl proto-oncogene in murine NK cell differentiation. J Immunol 1999;162:2761-5. (Pubitemid 29309300)
18. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852-4. (Pubitemid 34705057)
19. Rutqvist LE, Johansson H. Long-term follow-up of the Stockholm randomized trials of postoperative radiation therapy versus adjuvant chemotherapy among 'high risk' pre- and postmenopausal breast cancer patients. Acta Oncol 2006;45:517-27.
20. Spielmann M, Roche H, Delozier T, Canon JL, Romieu G, Bourgeois H, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009;27:6129-34.
21. Chaput N, Schartz NE, Andre F, Taïeb J, Novault S, Bonnaventure P, et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol 2004;172:2137-46. (Pubitemid 38182359)
22. Salaun B, Greutert M, Romero P. Toll-like receptor 3 is necessary for dsRNA adjuvant effects. Vaccine 2009;27:1841-7.
23. Salem ML, Kadima AN, Cole DJ, Gillanders WE. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother 2005;28:220-8. (Pubitemid 40593987)
24. Schulz O, Diebold SS, Chen M, Näaslund TI, Nolte MA, Alexopoulou L, et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005;433:887-92. (Pubitemid 40314900)
25. Tabiasco J, Devevre E, Rufer N, Salaun B, Cerottini JC, Speiser D, et al. Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor. J Immunol 2006;177:8708-13. (Pubitemid 44893836)
26. Honda K, Sakaguchi S, Nakajima C, Watanabe A, Yanai H, Matsumoto M, et al. Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc Natl Acad Sci U S A 2003;100:10872-7. (Pubitemid 37140120)
27. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 2009;206:1589-602.
28. Morikawa T, Sugiyama A, Kume H, Ota S, Kashima T, Tomita K, et al. Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Clin Cancer Res 2007;13:5703-9. (Pubitemid 47583894)
29. Khvalevsky E, Rivkin L, Rachmilewitz J, Galun E, Giladi H. TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. J Cell Biochem 2007;100:1301-12. (Pubitemid 46480411)
30. Yoneda K, Sugimoto K, Shiraki K, Tanaka J, Beppu T, Fuke H, et al. Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: differential signaling mechanisms of TLR3-induced NF-kappaB activation and apoptosis. Int J Oncol 2008;33:929-36.
31. Paone A, Starace D, Galli R, Padula F, De Cesaris P, Filippini A, et al. Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis 2008;29:1334-42.
32. Rydberg C, Mansson A, Uddman R, Riesbeck K, Cardell LO. Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas. Immunology 2009;128:e600-11.